Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jourdan

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS StudyArnaud Pigneux, Marie C Béné, Philippe Guardiola, et al.
Blood|April 21, 2005
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemiaPierre Sujobert, Valerie Bardet, Pascale Cornillet-Lefebvre, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
Leukemia|March 27, 2026
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemiaLoïc Vasseur, Matthieu Duchmann, Nicolas Duployez, et al.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Nature Communications|February 25, 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsJane Merlevede, Nathalie Droin, Tingting Qin, et al.
Blood|April 29, 2016
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLPhilippe Rousselot, Marie Magdelaine Coudé, Nicola Gokbuget, et al.
Haematologica|March 9, 2023
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 studyCorentin Orvain, Sylvain Chantepie, Xavier Thomas, et al.
Blood|October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS StudyArnaud Pigneux, Marie C Béné, Philippe Guardiola, et al.
Blood|April 21, 2005
Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemiaPierre Sujobert, Valerie Bardet, Pascale Cornillet-Lefebvre, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2018
Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO TrialArnaud Pigneux, Marie C Béné, Louis-Rachid Salmi, et al.
Leukemia|March 27, 2026
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemiaLoïc Vasseur, Matthieu Duchmann, Nicolas Duployez, et al.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Nature Communications|February 25, 2016
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsJane Merlevede, Nathalie Droin, Tingting Qin, et al.
Blood|April 29, 2016
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLPhilippe Rousselot, Marie Magdelaine Coudé, Nicola Gokbuget, et al.
Haematologica|March 9, 2023
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 studyCorentin Orvain, Sylvain Chantepie, Xavier Thomas, et al.
Blood|October 5, 2018
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
Pageof 9